{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010544","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.714309+00:00","generated_at":"2026-06-17T07:01:50.617705+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PAVmed Subsidiary Lucid Diagnostics Announces Medicare Coverage Determination for Esophageal Cancer Testing","bullets":["MolDX Program published Future Effective Local Coverage Determination L39256 on March 30, 2023","Coverage applies to molecular testing for esophageal precancer and cancer in Medicare beneficiaries","Determination becomes effective May 14, 2023","Lucid Diagnostics is a majority-owned subsidiary of PAVmed Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010544","json":"https://secwatch.observer/filing/0001493152-23-010544.json","markdown":"https://secwatch.observer/filing/0001493152-23-010544.md","text":"https://secwatch.observer/filing/0001493152-23-010544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223010544/0001493152-23-010544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223010544/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:01:50.617705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}